drugset / Trial / NCT06901999
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as an open-label, prospective, single-arm, single-center trial aimed at evaluating the efficacy and safety of MTX or Thiotepa combined with Orelabrutinib and standard chemotherapy regimens in the treatment of DLBCL patients with central nervous system involvement.
Timeline
- Start
- 2025-04
- Primary completion
- 2026-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 3.5 g | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Subject | Prednisone | Other / unclassified | 100 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 40 mg/m2 | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |